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To evaluate differences among patients with different clinical features of ALS, we 
used our Bayesian method of motor unit number estimation (MUNE). We performed 
serial MUNE studies on 44 subjects who fulfilled the diagnostic criteria for ALS 
during the course of their illness. Subjects were classified into three subgroups 
according to whether they had typical ALS ( with upper and lower motor neurone 
signs) or had predominantly upper motor neurone with only minor LMN feature, or 
predominantly lower motor neurone signs with only minor UMN signs. In all subjects 
we calculated the half life of MUs, defined as the expected time for the number of 
MUs to halve, in one or more of the abductor digiti minimi (ADM), abductor pollicis 
brevis (APB) and extensor digitorum brevis (EDB) muscles. The mean half life of 
motor units was less in subjects who had typical ALS with both upper and lower 
motor neurone signs than in those with predominantly upper motor neurone weakness 
or predominantly lower motor neurone weakness. In 18 subjects we analysed the 
estimated size of the MUs and demonstrated the appearance of large MUs in subjects 
with upper or lower motor neurone predominant weakness. We found that the 
appearance of large MUs was correlated with the half life of MUs. 
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Amyotrophic Lateral Sclerosis (ALS) is characterized by progressive loss of upper 
and lower motor neurones. The pathogenesis of ALS is unknown but inherited 
abnormalities of neuronal proteins are increasingly seen to be important [1]. The 
clinical picture of ALS results from dysfunction of both UMNs and LMNs. There has 
been debate as to whether the death of lower motor neurones (LMNs) is secondary to 
dying back of axons or dying forward of upper motor neurones (UMNs) or a 
combination of the processes [2].   
 
ALS is diagnosed on clinical grounds for which there are accepted criteria [3] . There 
are other diseases of motor neurones, which do not fulfill these criteria, with pure 
UMN disease (primary lateral sclerosis) or pure LMN weakness (progressive 
muscular atrophy). However, even when defined according to the standard criteria [3], 
ALS is heterogeneous with respect  to whether patients have typical ALS with mixed 
upper and lower motor neurone signs or whether UMN or LMN signs are 
predominant [4-7]. Clinical distinctions are important because it is possible that 
subjects with different clinical features have different underlying pathophysiology.   
 
One pathophysiological finding is that large MUs that can be demonstrated by needle 
EMG in ALS [8]. This is thought to occur because after denervation of muscle, there 
is often re-innervation due to collateral sprouting of terminal branches of surviving 
axons.   MU size in ALS has also been studied with decomposition-based quantitative 
electromyography (DQEMG)  [9]. However, there have been no studies of the size of 
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the entire population of motor unit action potentials (MUAPs) in ALS and the 
relationship of change in size of MUs to the rate of progression of disease.  
 
We have developed a Bayesian statistical technique of motor unit number estimation 
(MUNE) that gives an estimate of the number of MUs in a muscle [10;11]. As well as 
estimating the number of MUs, our MUNE technique also estimates the size of all the 
surface-recorded MUAPs that contribute to the CMAP. We have performed a large 
study with serial MUNE recordings from patients with ALS, to compare the rate of 
loss of MUs in different clinical subtypes and different muscles and to evaluate the 
changes in size in MUs as disease progresses.  
 
Methods 
Subjects and clinical assessment 
We recruited ALS patients who were attending the Motor Neurone Disease 
multidisciplinary clinic at the Royal Brisbane and Women’s Hospital (RBWH). The 
study was approved by the Hospital Ethics Committee and all subjects gave written 
consent prior to testing.  ALS patients met the modified El Escorial criteria for 
probable or definite ALS during the course of their disease  [3]. We noted the age at 
onset of ALS, site of onset as bulbar, upper limb (UL) or lower limb (LL) and length 
of symptom duration before the first visit (in months).  
 
The presence of UMN and LMN signs was evaluated. Signs of UMN involvement 
were taken to be spastic dysarthria, increased jaw jerk, emotional lability, 
hyperreflexia in the limbs, increased muscle tone, and clonus. Signs of LMN 
Lower motor neuron degeneration in ALS 5 
involvement were taken to be muscle atrophy and fasciculation. Patients with typical 
ALS with mixed UMN and LMN signs were grouped as typical ALS (ALS-typical).   
 
Patients with predominantly UMN signs were designated as UMN dominant type 
(UMN-D). Patients with UMN-D had symptoms less than 4 years, and disability due 
predominantly to UMN signs but with minor EMG denervation or LMN signs on 
examination. In these patients LMN signs of wasting and fasciculations limited to one 
or two muscles or minor denervation on EMG limited to sparse fibrillation potentials, 
positive sharp waves or minor MU potential remodelling on one or two muscles [4]. 
In assigning subject to UMN-D we did not include patients with clinically pure PLS 
[4]. 
 
Patients with predominantly LMN signs were designated LMN dominant type (LMN-
D). Patients with LMN-D had symptoms and disability due to prominent lower motor 
signs (muscle atrophy, fasciculations) at the time of first study, with no or minor 
UMN signs (emotional lability, hyperreflexia, spasticity). LMN-D patients were 
distinguished from pure adult onset LMN syndromes such as progressive muscular 
atrophy (PMA) patients who have disease duration of at least 4 years and absence of 




MUNE studies were performed in three different nerve/muscle combinations: median 
nerve / abductor pollicis brevis (APB) muscle, ulnar nerve/ abductor digiti minimi 
(ADM) / ulnar nerve and peroneal nerve /extensor digitorum brevis (EDB) muscle.   
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Surface recordings using the belly–tendon configuration were made from APB, ADM, 
and EDB muscles with disposable silver pre-gelled, 20mm diameter self adhesive 
electrodes (Nicolet Biomedical, Madison, Wisconsin). All studies were performed 
using a Nicolet Viking IV machine. The recording electrode was placed over the 
middle of the belly of the muscle (with attention to the muscle end plate). Before 
placing the electrodes, the skin was cleaned to prevent high or mismatching 
impedance between the electrodes. In all studies, the skin temperature was recorded 
with a surface probe and was maintained above 31 °C for the hand and 29 °C for the 
foot. The muscle under testing was restrained with a Velcro strap, and the audiometer 
was used to detect movement [13]. The active stimulating electrode was taped 
approximately 7 cm from the active recording electrode. The stimulus intensity was 
measured as current (mA) in constant voltage mode, and stimuli were 0.1 ms in 
duration. The frequency of stimulation was 2 Hz.  
 
For MUNE studies, a stimulus response curve with 1000 stimuli was first obtained as 
described previously [14;15]. The size of the stimulus required to produce a maximal 
CMAP was determined with standard NCS. For the stimulus response curve, the 
maximal CMAP was obtained with a stimulus strength sufficiently above the maximal 
(at least 10—20%) that small movements of stimulating electrodes would be unlikely 
to affect the maximal CMAP. For each study the minimum and maximum stimulus 
intensity was determined before commencing collection of the stimulus–response 
curve by gradually increasing the stimulus intensity with at least 1000 stimuli. A 
software modification supplied by Nicolet Biomedical (Madison, Wisconsin) was 
used to collect the stimulus response curves, by automatically evoked incremental 
stimuli. The CMAP amplitude measurements were automatically calculated from 
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baseline to negative peak. The areas and durations of the negative phase of the CMAP 
were measured from onset to baseline crossing. 
 
MUNE calculations  
Bayesian MUNE analysis was applied to the stimulus response curves, as  previously 
published [10;11]. In the present study, on the basis of our experience with the 
technique, we have modified the analysis by making a direct recording of the baseline 
noise (rather than estimating this in the model), by making the variability of the 
CMAP be the same across the entire CMAP scan, rather than increasing linearly with 
the number of units firing, and by prohibiting MUs with excitability curves that 
extend across the whole stimulus range.  
 
The MUNE method is based on mathematical model of MU activation, and uses the 
data from the stimulus response curve to estimate the unknown parameters of the 
model [16]. These parameters include the number of MUs and the size of the MUAPs.  
The size of the MUAPS are obtained by first obtaining the most probable number of 
MUs and using this as a fixed value in the model to estimate the average sizes of 
individual MUAPs over a further 10,000 iterations of the programme.  
 
Calculation of half-life    
The modal value of the posterior distribution of the number of MUs at each study was 
used to calculate the half life of MUs according to an exponential decay model in the 
nerve with more than 3 studies. The half life of the MU number was calculated as 
loge2 / (exponential rate of decline or decay constant). 
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Half life according to clinical group   
To determine whether the half lives of MUs in ALS was related to clinical features, 
the mean half lives of MUs among the three clinical groups was compared. The mean 
survival for these groups was also calculated.  
 
Studies of MUAP size at different time points    
In ALS subjects and healthy controls, we obtained histograms of individual estimated 
MU sizes for three different time points. We analysed these according to the clinical 
subtypes of ALS. For each study we calculated the median value of the MUAP size. 
We also assigned a value of size of 1000 microVms as a cut-off for large MUs, and 
for each study we calculated the percentage of MUs that had an area > 1000 
microVms.    
Statistical methods 
Descriptive statistics are presented as mean and standard deviation or standard error 
of mean for continuous variables and proportions for categorical variables. Multiple 
comparisons among different nerves and clinical subtypes were made by one-way 
analysis of variance (ANOVA).  
 
To see if the percentage of large MUs (defined as > 1000 microVms) was associated 
with the half life, we calculated the correlation co-efficient between the two measures 




Subjects and clinical features 
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We studied 44 subjects with a diagnosis of ALS. One of these patients had familial 
ALS with a rare SOD1 mutation with long survival  [17] and the other subjects had  
sporadic ALS. Other results from this cohort have been published previously 
(Baumann et al. submitted). All subjects had MUNE studies at least 4 times at 
intervals of three to four months. Some patients had two muscles studied at each 
neurophysiology session. Table 1 shows the clinical features of ALS subjects 
including the age, gender, site of onset, time from onset of symptoms at the start of 
study and survival time. The mean (SD) age of the subjects was 59 (11) years. There 
were more males (n= 30) than females (n= 14).  
 
On the basis of clinical observation, 18 patients were classified as having typical 
mixed ALS, 12 had predominant UMN signs (UMN-D) and 14 had predominant 
LMN signs (LMN-D). This classification was made prior to MUNE testing. 
 
The half life in clinical subtypes of ALS   
The mean (SD) half-life of MUs in all muscles (57 studies) in subjects with ALS-
typical, those with LMN-D and those with UMN-D were 235 (151), 448 (219) and 
979 (368) days, respectively. The half life of MUs was significantly less in subjects 
with ALS-typical than in subjects with LMN-D or UMN-D (Figure 1).  
 
In the typical ALS group, we studied 16 ADM (55%), 7 APB and 6 EDB muscles. In 
LMN- D group, 12 ADM (68%), 1 APB and 4 EDB muscles were studied. In UMN –
D group, 8 ADM (66%) and 4 APB muscle studies were used to calculate half life of 
MUs. Therefore the majority of studies were from ADM muscle in each subgroup. 
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The mean (SD) survival times of subjects with ALS-typical, LMN-D and UMN-D 
were 999 (311), 1443 (679) and 1614 (608) days, respectively. The survival time of 
subjects with ALS-typical was significantly shorter than those with LMN-D or UMN-
D type (Figure 2).  
 
We also compared the half lives of MUs of men (n=30) and women (n=14)  as shown 
in Table 2 for the whole group and for each of the subgroups.  There was no 
significant difference in half life of MUs in males (mean=419 days) and females 
(mean=366 days) (p=0.5).  
 
Studies of MUAP size at different time points:    
For this part of the study we used subjects who had serial testing of the ulnar nerve/ 
ADM muscle. There were 8 subjects with ALS-typical, 4 with UMN-D, 4 with LMN-
D and 8 healthy controls. For this analysis we used the MUNE studies at three time-
points. The mean interval from onset of symptoms to the first study was 14 (SD 6) 
months for typical ALS, 22 (SD 6) months for UMN-D patients and 20 (SD 11) 
months for LMN-D patients.  The second studies were done at a mean (SD) of 6 (2), 7 
(4) and 8 (3) months after the first study for typical, UMN-D, and LMN-D 
respectively. The third studies were done at a mean of 5 (2), 9 (2) and 11 (9) months 
after the second study for typical, UMN-D, and LMN-D respectively. 
 
For each subject, at each time-point the median and range in MUAP size was 
calculated. Figure 3 shows examples of the distribution of MUAP sizes and 
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representative subjects with ALS-typical, UMN-D and LMN-D types of disease, each 
at two time-points.  
 
The mean values of the median MU size and the percentage of large MUs at each 
time-point for each type are shown in Figure 4.  In the three groups of subjects with 
ALS, there was a large range of values for MU size, with some subjects having large 
median size and some subjects having a large percentage of large MUs compared to 
healthy subjects. This was most obvious in the UMN-D and LMN-D groups which 
also had larger MUs than those in the ALS-typical group. At the third study, there was 
a decline in the percentage of large units in 3 of the 8 subjects with typical ALS. In 
the groups with UMN-D and LMN-D the percentage of large units at the third study 
was greater than at the previous studies for all subjects.  
 
For each subject we calculated the ratio of the values at the second and third time-
points to the values at the first time-point. For each group we then calculated the mean 
and standard deviation of these ratios and these are shown in Table 3.  
 
Relationship of frequency of large MUs to rate of progression  
To determine if the percentage of large MUAPs was related to the half–life of MUs 
we calculated the percentage of large MUAPs (defined as being greater than 1000 
microVms) at the second study. We chose to use the data from the second study 
because at the third study some subjects showed a decline in the number of large 
MUs, as can occur at the pre-terminal stage of disease. We plotted the percentage of 
large MUs against half life of MUs in 18 patients (Figure 5). There was a significant 
correlation between percentage of large MUAPs and half life of MUs (r = 0.70).  
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Discussion 
In this study we have used our MUNE technique to show that the half-life of motor 
units and the accumulation of large motor units varies among subtypes of ALS. The 
results are based on our Bayesian MUNE method which is based on a model of motor 
unit activation, and leads to an estimate of the numbers and size of MUs in a muscle.  
We have previously explained the biological basis of our model and the underlying 
assumptions, and how we account for the variables in MU activation including 
variation in the threshold of axons and variation in the size of motor units [16;18].  
We have previously shown with serial studies of the number of MUs in a muscle, that 
the loss of MUs is well-fitted by an exponential decay curve (Baumann et al. 
unpublished data).   The demonstration that MU loss follows an exponential decay 
allows us to estimate the half-life of MUs.  
 
 
We found that patients with different clinical features differ in the rate of loss of MUs.  
In patients with typical ALS (with UMN and LMN signs) the half life of MUs was 
less than in subjects with UMN or LMN predominant disease. Our study of the half-
life provides electrophysiological evidence that supports clinical studies showing  that  
patients with predominance of UMN involvement have a more benign course [19] and 
longer survival than subjects with typical ALS  [20] and that subjects with LMN 
weakness have a slower rate of progression than subjects with typical ALS  [12].  
Although there are differences in the prevalence of ALS in men and women, and men 
and women differ in the site of onset of disease, with bulbar onset being more 
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common in older women [21] there was no difference between men and women in the 
half lives of MUs in the subjects that we studied.  
 
We also used our MUNE method to study the size of MUAPs in ALS subjects, 
although this study has the   limitation that recording from surface electrodes may 
underestimate the size of distant action potentials. MUs are known to vary in size 
from moment to moment [22], so in our model we allow MUs to vary in size, and the 
results we present are the average of 10,000 estimations.  
 
There was an increase in the percentage of large motor units over time in subjects 
with all subtypes of ALS, with the percentage of large MUAPS correlated with the 
half life. This was variable among subjects reflecting the heterogeneity of disease. 
However, in a few of the subjects with typical ALS, there was a decline in the number 
of large MUs at the third study. There was an increase in the median size of MUs, 
particularly in subjects with UMN-D and LMN-D type of disease, and in some 
subjects with ALS-typical. These findings are consistent with current understanding 
of ALS [8;23;24] where collateral sprouting leads to an increased fibre density of 
MUs  [25;26].  We found that the increase in MUAP size in the early stages of lesion, 
reflecting re-innervation, was much greater in LMN predominant subtype than typical 
ALS, consistent with previous reports  [27]. These UMN-D and LMN-D subjects 
differ from typical ALS subjects in having a longer half life, and were also studied at 
longer times after onset of disease. We suggest that the slower and longer disease 
process allows collateral sprouting to occur in these subjects. We found that the 
percentage of large MUs was related to the half-life of MUs. 
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In previous studies, a modest increase in MU size was found using the multiple point 
stimulation MUNE method [28-30]  . A previous multicentre serial MUNE study 
using the Poisson statistical method did not find an increase in mean MUAP size over 
time [31], perhaps because the effect of MU variability could not be included in the 
calculation.  Others have shown an increase in MU size over time, using the MPS 
method which measures the size of a sample of MUs, rather than the whole 
population as is the case with our method, although in some subjects the size of the 
MUs declines at the end stage of disease [9;30].    
 
These differences in length of survival, rate of progression and the accumulation of 
large MUs could indicate that there are underlying pathophysiological differences 
among these groups. Indeed, post-mortem studies have found that subjects with 
typical ALS differ from those with LMN predominant form of ALS in the pattern of 
neuronal loss, providing evidence that the clinical signs of disease reflect the pattern 
of neuronal loss in ALS [32]. In UMN dominant ALS, a benign LMN impairment 
involving only few motor units and leaving the others intact was a common feature 
[33]. Similarly a post-mortem study showed LMN loss was minimal in patients whose 
motor manifestations had been predominantly UMN type [34]. Recently subjects with 
UMN predominant disease have been found to have genetic variation in the KIFAP3 
[35]. Although the classification into the subtypes of MND was based on clinical 
assessment, this reflects the clinical heterogeneity of the disease and is an approach 
being used by others. In summary, our MUNE analysis appears to be a feasible 
method to provide new insights into the pathophysiology of lower motor neuron 
degeneration and MU re-arrangement in ALS. 
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ADM - abductor digiti minimi  
 
APB - abductor pollicis brevis 
 
ALS – amyotrophic lateral sclerosis 
 
CMAP – compound muscle action potential  
 
EDB - extensor digitorum brevis 
 
FDI – first dorsal interosseous 
 
LMN – lower motor neurone 
 
LL – lower limb 
 
MN - motor neurone 
 
MU – motor unit 
 
MUAP – motor unit action potential 
 
MUNE – motor unit number estimate 
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PLS - primary lateral sclerosis 
 
PMA – progressive muscular atrophy 
 
TA – tibialis anterior 
 
UL – upper limb 
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Figure 1.  Half life of MUs according to type of ALS. 
The half life of MUs among three clinical subtypes (ALS-typical, UMN-D LMN-D ) 
was compared. There was significant difference in half lives among these three 
subtypes (p< 0.05). 
 
Figure 2.  Survival time according to type of ALS 
The mean survival time for these groups was also calculated (D). The survival time of 
subjects with typical ALS was significantly shorter than those with predominantly 
lower (LMN-D) or predominantly upper motor neurone (UMN- D) weakness.  
The bottom and top of the boxes are the 25th and 75th percentile (the lower and upper 
quartiles, respectively), and the band near the middle of the box is the 50th percentile 
(the median). The whiskers represent the minimum and maximum of all the data. 
 
Figure 3. Frequency distribution of MU sizes  
Examples of the distribution of single MUAP areas of a subjects with typical ALS (C, 
D), LMN-D disease (E, F) and UMN-D (G, H) type of disease, showing studies at the 
as the mid stage of disease (study 1) and end stage (study 2) of disease. MU size is 
given as area (micoVms). 
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Dotted lines represent the distribution curves. The LMN and UMN predominant 
patients had very large MUs  (> 3000) at the early stages (E, G) and there were almost 
only large MUs (> 1000), up to 7000uVms (F,H) whereas the typical ALS patient had 
no large MU at the end stage (D). 
 
 
Figure 4. MUAP size in subtypes of ALS during disease progression. 
The graph of the mean of the median MUs sizes (upper panel) and the mean 
percentage of large MUs (lower panel) in healthy controls and three groups of ALS 
subjects (typical ALS, UMN-D, LMN-D) at early, mid and late stages of the disease.  
Error bars represent ± SD 
 
Figure 5. The correlation of the half life of MUs and the percentage of large 
MUs. The percentage of large units (> 1000 microVms) at the second study in 18 
ALS subjects was plotted against half life of MUs. There was significant correlation 
between percentage of large MUs and the half life of MUs (r = 0.70). 
 
 





Table 1. Clinical features of ALS subjects  
 
 
Number of subjects  
 
 
Total number of subjects  44 
No (%) males 30 (68) 
 
Age of onset and symptom duration  
 
 
Mean (sd) Age of onset (yr) 59 (11)  
Range of age of onset (yr) 30-81 
Duration of symptoms at study entry (mo) 15 (11) 
Range of symptom onset (mo) 3-62 
 
Site of onset 
 
 
No (%) bulbar onset 12 (27) 
No (%) upper limb onset 15 (35) 





No.(%) with Typical ALS                               18 (41) 
No (%) with UMN predominant 14 (32) 





Mean (sd) survival time (mo) 41 (15) 
Range 18-89 




† Symptom duration is from the onset of disease to the first MUNE study 
‡ Survival time is calculated from the symptom onset to death in deceased patients and 












Table 2. Half-life of MUs  according to clinical subtype and gender 




Total group males 
 
30 419 299 
Total-group females  
 
14 366 271 
ALS-typical males 
 
13 217 98 
ALS-typical females 
 
5 204 44 
LMN-D males 
 
9 503 210 
LMN-D females 
 
5 297 117 
UMN-D males 
 
8 652 397 
UMN-D females 
 
4 654 369 
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Table 3 Ratio of median size of motor units and ratio of percentage of large motor 
units at study 2 and study 3 to values at first study 
Patient group Mean ratio of 
median MU size at 
second study to 
median MU size at 
first study 
Mean ratio of 
median MU size at 
third study to 
median MU size at 
first study 
Mean ratio of 
percent large 
units at second 
study to 
percent large 
units at first 
study 
Mean ratio of 
percent large 
units at third 
study to 
percent large 
units at first 
study 
ALS-typ 1.29 (0.26) 1.52 (1.02) 2.20 (3.00)  2.71 (4.10) 
UMN-D 1.03 (0.27) 1.59 (0.47) 1.20 (0.17) 1.51 (0.33) 
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